Spotlight: HHS & VA Announce Bold, Comprehensive Partnership to Advance Rapid-Acting Mental Health Treatments for Veterans
Health & Human Services & The Veterans Administration join the Food and Drug Administration in new announcements surrounding psychedelics for mental health
https://www.hhs.gov/press-room/hhs-va-partner-advance-psychedelic-therapies-veterans.html
"Together, the Departments will prepare for the deployment of future FDA-approved rapid-acting psychiatric drug products for serious behavioral health conditions by:
- Increasing participation in clinical research on promising rapid-acting mental health treatments for veterans
- Training therapists, nurses, physicians, and other clinicians to safely administer future FDA-approved rapid-acting psychiatric drug products
- Collecting and sharing real-world data on the safety, effectiveness, and costs of these treatments to improve patient care and inform future policy
- Coordinating research and sharing evidence as appropriate and consistent with legal authority that may help inform future FDA regulatory decisions and coverage policies
- Developing clinical guidance and educational resources to help providers — and ultimately patients — understand how approved treatments should be delivered safely and effectively
The agreement remains in force for five years, with the option to renew."